Crossmark

1351 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3xB7H4 in solid cancer models

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1351

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Koopman, Louise

Paauwe, Madelon

Vries, Laura Smits-de

Karaiskaki, Frosso

Brandhorst, Marcel

Franken, Patrick

Plantinga, Theo

Poot, Stefanie De

Houtkamp, Mischa

Sasser, Kate

Breij, Esther
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05180474 at ClinicalTrials.gov

Documents that mention this clinical trial

1351 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3xB7H4 in solid cancer models
https://doi.org/10.1136/jitc-2022-sitc2022.1351